TTrialPathMatch Me to Trials
← Back to trials
RecruitingHealthy VolunteerAtopic Dermatitis

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

Eligible age

18–65 yrs

Accepts

All genders

Locations

7 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will test an experimental study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies. REGN20423 has not previously been studied in humans. The study is looking at: * What side effects REGN20423 might cause * How much REGN20423 is in the blood at different times * How well REGN20423 works in adults with atopic dermatitis * Whether the body makes antibodies against REGN20423 * How the body changes after having REGN20423, which can help researchers understand why REGN20423 works better in some people than others * What the best dose of REGN20423 is

Sponsor: Regeneron Pharmaceuticals

Where it's recruiting

Alabama

Birmingham

Arkansas

North Little Rock

California

West Hills

Florida

Miami · Weston

Georgia

Union City

South Carolina

North Charleston

Texas

San Antonio

Source: ClinicalTrials.gov · NCT07527923 · last updated 2026-11-06

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants · TrialPath